依洛尤单抗注射液治疗冠心病合并高脂血症患者的临床观察  

Clinical Effect of Evolocumab Injection in Patients With Coronary Heart Disease and Hyperlipidemia

作　　者：张冬青 张尉华[1] ZHANG Dongqing;ZHANG Weihua(Department of Cardiology,The First Hospital of Jilin University,Changchun Jilin 130021,China;Department of Cardiology,Jilin Province FAW General Hospital,Changchun Jilin 130011,China)

机构地区：[1]吉林大学第一医院心内科,吉林长春130021 [2]吉林省一汽总医院心内科,吉林长春130011

出　　处：《中国卫生标准管理》2022年第15期140-144,共5页China Health Standard Management

摘　　要：目的 观察应用依洛尤单抗注射液治疗冠心病合并高脂血症患者的临床疗效。方法 选择 2021 年 3—9 月于吉林大学第一医院就诊的冠心病合并高脂血症患者 80 例,随机分为对照组(阿托伐他汀组)40 例和依洛尤单抗治疗组 40 例,治疗 3 个月,观察两组患者治疗前后血脂变化情况。结果 依洛尤单抗治疗组患者血脂改善情况总有效率为 92.5%,对照组的总有效率 75.0%,依洛尤单抗治疗组总有效率显著优于对照组,差异有统计学意义(χ^(2)=4.501,P=0.034);两组患者治疗后总胆固醇(total cholesterol,TC)、甘油三酯(triglycerides,TG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)较治疗前有显著降低,高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)有明显升高,差异有统计学意义(P < 0.05),且依洛尤单抗治疗组治疗后 TC、TG、HDL-C 及 LDL-C 较对照组治疗后改善更加显著,差异有统计学意义(P < 0.05)。结论 应用依洛尤单抗注射液治疗冠心病合并高脂血症患者,患者的血脂情况明显改善,临床疗效显著。Objective To observe the clinical effect of evolocumab injection in patients with coronary heart disease and hyperlipidemia.Methods A total of 80 patients with coronary heart disease complicated with hyperlipidemia who visited The First Hospital of Jilin University from March to September 2021 were selected and randomly divided into the control group(atorvastatin group) with 40 cases and the evolocumab treatment group with 40 cases. After 3 months of treatment, the changes of blood lipids in the two groups before and after treatment were observed. Results The total effective rate of blood lipid improvement in the evolocumab treatment group was 92.5%,and the total effective rate in the control group was 75.0%. The total effective rate of the evolumab treatment group was significantly better than that of the control group, and the difference was statistically significant(χ^(2)=4.501, P=0.034). After treatment, total cholesterol(TC),triglycerides(TG) and low density lipoprotein cholesterol(LDL-C) in both groups were significantly lower than those before treatment, high density lipoprotein cholesterol(HDL-C) was significantly increased,and the differences were statistically significant(P < 0.05). After treatment, TC, TG, HDL-C and LDL-C in the evolocumab treatment group were improved more significantly than those in the control group,and the difference was statistically significant(P < 0.05). Conclusion The application of evolocumab injection in the treatment of patients with coronary heart disease complicated with hyperlipidemia can significantly improve the blood lipid status of the patients, and the clinical effect is significant.

关 键 词：依洛尤单抗注射液 PCSK9抑制剂 阿托伐他汀 高脂血症 冠心病 临床观察 

分 类 号：R544[医药卫生—心血管疾病]